This study is testing a drug called CDX-622 in adults with mild to moderate asthma. CDX-622 is a bispecific antibody, meaning it can target two different things in the body (stem cell factor and thymic stromal lymphopoietin). Researchers want to see how safe CDX-622 is and how well people tolerate it. You might be able to join if you are at least 18 years old, have had mild to moderate asthma for at least a year, and meet certain lung function requirements (like your FEV1, a measure of how much air you can exhale in one second, being at least 70% of normal). The study aims to enroll 12 participants. The current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It will involve a small number of participants, with a planned enrollment of 12 people.

What's involved

Participants will receive a single dose of CDX-622 through an IV (intravenous) infusion. You will have follow-up visits for up to 12 weeks after the infusion.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 85 days (12 weeks) after receiving the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.